01—Abstract
Summary
Summary of the 10-K filed February 22, 2019. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (filed under the name Exelixis, Inc.) is an oncology-focused biotechnology company whose 2018 results were driven by its flagship molecule cabozantinib, marketed as CABOMETYX for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC), and as COMETRIQ for medullary thyroid cancer.
For 2018, total revenues were $853.8 milliona, up from $452.5 million in 2017, and net product revenues were $619.3 million, up from $349.0 million. Net income was $690.1 million, or $2.21 per diluted share, compared with $154.2 million, or $0.49 per diluted share, in 2017. The filing states that the result includes a $244.1 million income tax benefit from the release of substantially all of the valuation allowance against deferred tax assets, and that from 2019 the company expects to record income tax expense at an estimated effective rate between 21% and 23%.
The company ended 2018 with $851.6 millionb in cash and investments, up from $457.2 million a year earlier, and states that it expects its current cash, short-term investments and revenues to fund operations for at least 12 months after the filing date. Its partner-driven revenue base includes Ipsen (outside the U.S. and Japan), Takeda (Japan), and Genentech (cobimetinib, marketed as COTELLIC). The company also reports an FDA approval of CABOMETYX for previously treated HCC on January 14, 2019, supported by the phase 3 CELESTIAL trial, and a broad development program of over 75 ongoing or planned cabozantinib trials, including phase 3 studies COSMIC-311, COSMIC-312 and CheckMate 9ER.
The filing highlights key risks: dependence on CABOMETYX's commercial success, intense competition from immune checkpoint inhibitors and other TKIs, reliance on collaboration partners, pricing and reimbursement pressure, and patent exposure, including generic entry risk. The company's composition-of-matter patent for cabozantinib is listed with expiration in 2026 following a patent term extension.
02—Key points
Key Highlights
- Total revenues rose to $853.8 million in 2018 from $452.5 million in 2017; net product revenues rose to $619.3 million from $349.0 million.
- CABOMETYX net product revenues were $599.9 million in 2018 versus $324.0 million in 2017; COMETRIQ net product revenues were $19.3 million versus $25.0 million.
- Net income was $690.1 million ($2.21 per diluted share) in 2018, including a $244.1 million income tax benefit from releasing most of the deferred tax valuation allowance.
- Cash and investments totaled $851.6 million at December 31, 2018, compared with $457.2 million at December 31, 2017.
- The FDA approved CABOMETYX on January 14, 2019 for HCC patients previously treated with sorafenib, based on the phase 3 CELESTIAL trial.
- The company is running more than 75 ongoing or planned cabozantinib trials, including phase 3 studies COSMIC-311 (differentiated thyroid cancer), COSMIC-312 (first-line HCC) and CheckMate 9ER (first-line RCC).
- The company expects its effective tax rate to be between 21% and 23% starting in 2019, which will reduce net income compared with the 2018 tax benefit.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2018, Exelixis kept $0.81.
- Revenue$853.8M100.0%
- Cost of revenue−$26.3M3.1%
- Gross profit$827.5M96.9%
- Operating costs−$388.6M45.5%
- Operating income$438.9M51.4%
- Interest, other & tax$251.2M29.4%
- Net income$690.1M80.8%
Where FY2018 revenue went
$853.8M- Operating income: $438.9M, 51% of revenue
- SG&A: $206.4M, 24% of revenue
- R&D: $182.3M, 21% of revenue
- Cost of revenue: $26.3M, 3.1% of revenue
Kept 51% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2018filed February 22, 2019Financial Statements
FY2018 against FY2017
| Line item | FY2018FY2017 | Change |
|---|---|---|
| Revenue | $853.83M$452.48M | +88.7% |
| Cost of Revenue | $26.35M$15.07M | +74.9% |
| Gross Profit | $827.48M$437.41M | +89.2% |
| R&D Expenses | $182.26M$112.17M | +62.5% |
| SG&A Expenses | $206.37M$159.33M | +29.5% |
| Operating Expenses | $414.97M$286.57M | +44.8% |
| Operating Income | $438.86M$165.91M | +164.5% |
| Interest Expense | $0$8.68M | −100.0% |
| Net Income | $690.07M$154.23M | +347.4% |
| EPS (Basic) | $2.32$0.52 | +346.2% |
| EPS (Diluted) | $2.21$0.49 | +351.0% |
| Shares Outstanding (Basic) | 297.89M293.59M | +1.5% |
| Shares Outstanding (Diluted) | 312.80M312.00M | +0.3% |
05—Questions
Frequently Asked Questions
What drove Exelixis's revenue growth in 2018?
Total revenues increased to $853.8 million from $452.5 million. Net product revenues rose 77% to $619.3 million, driven mainly by CABOMETYX unit growth in advanced RCC, and collaboration revenues rose to $234.5 million from $103.5 million, mainly from milestones under the Ipsen collaboration and royalties on Ipsen's sales.
Why was 2018 net income so much higher than 2017?
Net income was $690.1 million versus $154.2 million. The filing attributes part of the increase to a $244.1 million income tax benefit from releasing substantially all of the valuation allowance against deferred tax assets, along with higher total revenues and income from operations of $438.9 million.
What is the company's liquidity position?
At December 31, 2018, cash and investments were $851.6 million, of which $850.5 million was available for operations. The company anticipates these resources, together with product and collaboration revenues, will support operations for at least 12 months following the filing date.
What are the main risks to CABOMETYX's future growth?
The filing cites competition from immune checkpoint inhibitors and other TKIs, the evolving RCC treatment landscape, pricing and reimbursement pressure, dependence on partners Ipsen and Takeda for ex-U.S. commercialization, and the potential for generic competition. The company's composition-of-matter patent for cabozantinib is listed with expiration in 2026 after a patent term extension.
What regulatory milestones occurred around the filing date?
The FDA approved CABOMETYX for previously treated HCC on January 14, 2019, and the Japanese MHLW approved Daiichi Sankyo's MINNEBRO (esaxerenone) for hypertension in January 2019. The FDA also accepted the IND for XL092, the company's first internally discovered compound from its reinitiated drug discovery program.
06—Continue